JQKD 82 dihydrochloride

Key Product Details

Product Description

JQKD 82 dihydrochloride is cell-permeable, selective inhibitor of lysine demethylase 5 (KDM5). JQKD 82 does not show activity toward other KDMs; and it has selectivity for KDM5A over other KDM5 isoforms. JQKD 82 causes hypermethylation of H3K4me3, downregulation of MYC targets and RNAPII phosphorylation; it suppresses multiple myeloma cell (MM.1S) growth (IC₅₀ = 0.42 µmol/L). JQKD 82-treated tumors display an increase in H3K4me3 levels and results in a reduction of MYC immuno-staining in NSG mice.

Licensing Information

Sold under license from Dana-Farber Cancer Institute

Product Specifications for JQKD 82 dihydrochloride

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for JQKD 82 dihydrochloride

The following data is based on the product molecular weight 573.56.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.5 mM	3.49 mL	17.43 mL	34.87 mL
2.5 mM	0.70 mL	3.49 mL	6.97 mL
5 mM	0.35 mL	1.74 mL	3.49 mL
25 mM	0.07 mL	0.35 mL	0.70 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Ohguchi Lysine demethylase 5A is required for MYC driven transcription in multiple myeloma. Blood Cancer Discov. 2021 PMID: 34258103

Product Documents for JQKD 82 dihydrochloride